J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503

摩根大通维持福泰制药(VRTX.US)买入评级，目标价503美元

moomoo资讯 · 2024/11/06 08:37 · 评级/大行评级

J.P. Morgan analyst Jessica Fye maintains $Vertex Pharmaceuticals (VRTX.US)$ with a buy rating, and sets the target price at $503.

According to TipRanks data, the analyst has a success rate of 52.0% and a total average return of 6.3% over the past year.

AnalystRecentRatingAutoNews_206501_20241105_9f259a6c34bbe445ffe6dd6c288bc370a2bc4574_1730899881281517_mm_en

Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:

Vertex Pharmaceuticals' Q3 results exceeded consensus expectations, and the company increased its 2024 revenue guidance slightly, by approximately 1% at the midpoint. The forthcoming suzetrigine Phase 2 lumbosacral radiculopathy (LSR) data, anticipated by the end of the year, is expected to be the next significant event for the company's stock.
The company's robust performance in cystic fibrosis, which surpassed expectations and led to a raised forecast, demonstrates the ongoing strength of its fundamental business. This is expected to continue supporting the stock's premium valuation. However, there are cautions that the outlook heading into FY25 may present more challenges compared to FY24, considering that upcoming data for suzetregine is anticipated to meet effectiveness criteria but may not generate significant enthusiasm, and the introductions of acute pain treatments and Casgevy are expected to experience gradual market penetration.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根大通分析师Jessica Fye维持$福泰制药 (VRTX.US)$买入评级，目标价503美元。

根据TipRanks数据显示，该分析师近一年总胜率为52.0%，总平均回报率为6.3%。

AnalystRecentRatingAutoNews_206501_20241105_9f259a6c34bbe445ffe6dd6c288bc370a2bc4574_1730899881281517_mm_sc

此外，综合报道，$福泰制药 (VRTX.US)$近期主要分析师观点如下：

福泰制药的第三季度业绩超过了共识预期，并且公司略微提高了2024年营业收入指引，中间值约增长1%。预计在年底之前公布的suzetrigine第2期腰脊神经根病（LSR）数据预计将成为公司股票的下一个重大事件。
公司在囊性纤维化业务领域表现强劲，超出预期并提高了预测，展示了其基本业务持续实力。预计这将继续支撑股票的溢价估值。然而，需要谨慎注意的是，与2024财年相比，展望进入2025财年可能会带来更多挑战，考虑到即将公布的suzetregine数据预计将满足有效性标准但可能不会激发太多热情，而急性疼痛治疗和Casgevy的推出预计将逐步获得市场渗透。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503

J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503

风险及免责提示

声明